{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:11:44Z","timestamp":1788487904670,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"European Union Seventh Framework Programme","doi-asserted-by":"crossref","award":["278742"],"award-info":[{"award-number":["278742"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.021","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T03:22:54Z","timestamp":1490930574000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"special_numbering":"C","title":["Giant cell tumour of bone in the denosumab era"],"prefix":"10.1016","volume":"77","author":[{"given":"Lizz","family":"van der Heijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.D. Sander","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.02.021_bib1","series-title":"WHO classification of tumours of soft tissue and bone","first-page":"321","article-title":"Giant cell tumour of bone","author":"Athanasou","year":"2013"},{"issue":"23","key":"10.1016\/j.ejca.2017.02.021_bib2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2106\/JBJS.N.00367","article-title":"Regional variation and challenges in estimating the incidence of giant cell tumor of bone","volume":"96","author":"Liede","year":"2014","journal-title":"J Bone Jt Surg Am"},{"issue":"21","key":"10.1016\/j.ejca.2017.02.021_bib3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2106\/JBJS.O.00156","article-title":"Incidence trends in the diagnosis of giant cell tumor of bone in Sweden since 1958","volume":"97","author":"Rockberg","year":"2015","journal-title":"J Bone Jt Surg Am"},{"issue":"16","key":"10.1016\/j.ejca.2017.02.021_bib4","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.021_bib5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2106\/JBJS.N.00678","article-title":"Risk factors for pulmonary metastases from giant cell tumor of bone","volume":"97","author":"Chan","year":"2015","journal-title":"J Bone Jt Surg Am"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00264-006-0204-x","article-title":"Histologically verified lung metastases in benign giant cell tumours\u201314 cases from a single institution","volume":"30","author":"Dominkus","year":"2006","journal-title":"Int Orthop"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.021_bib8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00432-008-0370-x","article-title":"Giant cell tumor of bone: treatment and outcome of 214 cases","volume":"134","author":"Balke","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2106\/JBJS.D.02771","article-title":"Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy","volume":"90","author":"Becker","year":"2008","journal-title":"J Bone Jt Surg Am"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/17453670710014815","article-title":"Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years","volume":"79","author":"Kivioja","year":"2008","journal-title":"Acta Orthop"},{"key":"10.1016\/j.ejca.2017.02.021_bib11","first-page":"2010","article-title":"High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis","author":"Algawahmed","year":"2010","journal-title":"Sarcoma"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2009.09.002","article-title":"Giant cell tumor of the extremity: a review of 349 cases from a single institution","volume":"36","author":"Errani","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.021_bib13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/17453674.2012.711193","article-title":"Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones","volume":"83","author":"Van der Heijden","year":"2012","journal-title":"Acta Orthop"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.021_bib14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11999-010-1501-7","article-title":"Giant cell tumor of bone: risk factors for recurrence","volume":"469","author":"Klenke","year":"2011","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect Tissue Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1148\/radiographics.21.5.g01se251283","article-title":"From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation","volume":"21","author":"Murphey","year":"2001","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1148\/rg.331125089","article-title":"Giant cell tumor of bone: review, mimics, and new developments in treatment","volume":"33","author":"Chakarun","year":"2013","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2214\/ajr.166.1.8571864","article-title":"MR findings indicative of hemosiderin in giant-cell tumor of bone: frequency, cause, and diagnostic significance","volume":"166","author":"Aoki","year":"1996","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1148\/radiology.208.3.9722866","article-title":"Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization?","volume":"208","author":"van der Woude","year":"1998","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0720-048X(00)00202-3","article-title":"Bone and soft tissue tumors: the role of contrast agents for MR imaging","volume":"34","author":"Verstraete","year":"2000","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.021_bib22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jmri.1880060210","article-title":"Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications","volume":"6","author":"Verstraete","year":"1996","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11604-006-0109-z","article-title":"Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress","volume":"25","author":"Kajihara","year":"2007","journal-title":"Radiat Med"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.021_bib24","first-page":"2199","article-title":"Metachronous, multicentric giant cell tumor of the sphenoid bone with histologic, CT, MR imaging, and positron-emission tomography\/CT correlation","volume":"27","author":"McKinney","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1148\/radiology.219.3.r01ma08774","article-title":"FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions","volume":"219","author":"Aoki","year":"2001","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00428-009-0863-2","article-title":"Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone","volume":"456","author":"Alberghini","year":"2010","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.021_bib27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00428-012-1235-x","article-title":"Smooth muscle actin expression in primary bone tumours","volume":"460","author":"Hemingway","year":"2012","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.021_bib29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0002-9440(10)63323-8","article-title":"Cathepsin K is the principal protease in giant cell tumor of bone","volume":"165","author":"Lindeman","year":"2004","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.021_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1684\/bdc.2011.1398","article-title":"The role of RANK\/RANKL\/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications","volume":"98","author":"Clezardin","year":"2011","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1359\/jbmr.080905","article-title":"CD33+ CD14\u2212 phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone","volume":"24","author":"Forsyth","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.021_bib32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/jcp.2011.090852","article-title":"The immunophenotype of osteoclasts and macrophage polykaryons","volume":"64","author":"Maggiani","year":"2011","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/jclinpath-2015-203248","article-title":"Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series","volume":"69","author":"Girolami","year":"2016","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2559.2011.03948.x","article-title":"Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone","volume":"59","author":"Balla","year":"2011","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.021_bib35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cancergencyto.2004.09.015","article-title":"Molecular analysis of primary and recurrent giant cell tumors of bone","volume":"158","author":"Rao","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.021_bib36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/gcc.20667","article-title":"Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations","volume":"48","author":"Gorunova","year":"2009","journal-title":"Genes Chromosom Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/path.2301","article-title":"Telomere biology in giant cell tumour of bone","volume":"214","author":"Forsyth","year":"2008","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.021_bib38","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.021_bib39","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","article-title":"Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma","volume":"39","author":"Cleven","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/gcc.20656","article-title":"Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis","volume":"48","author":"Moskovszky","year":"2009","journal-title":"Genes Chromosom Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002640050381","article-title":"The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone","volume":"23","author":"Antal","year":"1999","journal-title":"Int Orthop"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1046\/j.1365-2559.2001.01275.x","article-title":"Secondary malignant giant-cell tumour of bone: molecular abnormalities of p53 and H-ras gene correlated with malignant transformation","volume":"39","author":"Oda","year":"2001","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00428-014-1666-7","article-title":"Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis","volume":"465","author":"Lieveld","year":"2014","journal-title":"Virchows Arch"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.021_bib44","doi-asserted-by":"publisher","first-page":"e69101","DOI":"10.1371\/journal.pone.0069101","article-title":"Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy","volume":"8","author":"Steensma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2017.02.021_bib45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2407-11-241","article-title":"A short-term in\u00a0vivo model for giant cell tumor of bone","volume":"11","author":"Balke","year":"2011","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/03008207.2015.1075519","article-title":"A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone","volume":"56","author":"Lau","year":"2015","journal-title":"Connect Tissue Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The clinical approach toward giant cell tumor of bone","volume":"19","author":"van der Heijden","year":"2014","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.021_bib48","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/BRS.0b013e31819d4127","article-title":"Outcome of conservative surgery for giant cell tumor of the sacrum","volume":"34","author":"Guo","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.ejca.2017.02.021_bib49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00003086-200012000-00023","article-title":"Total sacrectomy and reconstruction: oncologic and functional outcome","volume":"381","author":"Wuisman","year":"2000","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.021_bib50","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1007\/s11999-010-1448-8","article-title":"Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor","volume":"468","author":"Ruggieri","year":"2010","journal-title":"Clin Orthop Relat Res"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.021_bib51","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1302\/0301-620X.97B11.35326","article-title":"Does pathological fracture affect the rate of local recurrence in patients with a giant cell tumour of bone? A meta-analysis","volume":"97-b","author":"Salunke","year":"2015","journal-title":"Bone Jt J"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib52","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s11999-012-2546-6","article-title":"Giant cell tumor with pathologic fracture: should we curette or resect?","volume":"471","author":"Van der Heijden","year":"2013","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2017.02.021_bib53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/BLO.0b013e31805d85e4","article-title":"Joint salvage for pathologic fracture of giant cell tumor of the lower extremity","volume":"459","author":"Deheshi","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2017.02.021_bib54","first-page":"275","article-title":"Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases","volume":"134","author":"Marcove","year":"1978","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2017.02.021_bib55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00003086-198501000-00021","article-title":"The closed cryosurgical treatment of giant cell tumor","volume":"192","author":"Jacobs","year":"1985","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s004020100317","article-title":"Oncologic and functional results after treatment of giant cell tumors of bone","volume":"122","author":"Boons","year":"2002","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.ejca.2017.02.021_bib57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00003086-199902000-00019","article-title":"Cryosurgery in the treatment of giant cell tumor. A long-term followup study","volume":"359","author":"Malawer","year":"1999","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.021_bib58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MOO.0b013e32834883f2","article-title":"Bone tissue substitutes and replacements","volume":"19","author":"Theler","year":"2011","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2017.02.021_bib59","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.2147\/IJN.S29314","article-title":"Osteogenic capacity of nanocrystalline bone cement in a weight-bearing defect at the ovine tibial metaphysis","volume":"7","author":"Harms","year":"2012","journal-title":"Int J Nanomed"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib60","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.knee.2007.07.001","article-title":"Use of a novel bone graft substitute in peri-articular bone tumours of the knee","volume":"14","author":"Schindler","year":"2007","journal-title":"Knee"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3171\/2014.10.SPINE13937","article-title":"Giant cell tumors of the spine: has denosumab changed the treatment paradigm?","volume":"22","author":"Goldschlager","year":"2015","journal-title":"J Neurosurg Spine"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.021_bib62","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.spinee.2014.02.019","article-title":"Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab","volume":"14","author":"Mattei","year":"2014","journal-title":"Spine J"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.021_bib63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/17453674.2014.1002345","article-title":"Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report","volume":"86","author":"van der Heijden","year":"2015","journal-title":"Acta Orthop"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin Sarcoma Res"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.021_bib65","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.021_bib66","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"9967","key":"10.1016\/j.ejca.2017.02.021_bib67","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(14)61338-6","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib68","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.021_bib70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3892\/ol.2012.1036","article-title":"Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates","volume":"5","author":"Yu","year":"2013","journal-title":"Oncol Lett"},{"issue":"14","key":"10.1016\/j.ejca.2017.02.021_bib71","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib72","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3928\/01477447-20150105-56","article-title":"Local administration of zoledronic acid for giant cell tumor of bone","volume":"38","author":"Nishisho","year":"2015","journal-title":"Orthopedics"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.021_bib73","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1007\/s00586-015-3978-y","article-title":"Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage","volume":"24","author":"Chen","year":"2015","journal-title":"Eur Spine J"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.021_bib74","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(13)70291-2","article-title":"Denosumab treatment of giant cell tumour of bone","volume":"14","author":"Balke","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.021_bib75","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00586-015-3834-0","article-title":"Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review","volume":"24","author":"Ma","year":"2015","journal-title":"Eur Spine J"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.021_bib76","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2106\/00004623-199911000-00008","article-title":"Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone","volume":"81","author":"Chakravarti","year":"1999","journal-title":"J Bone Jt Surg Am"},{"key":"10.1016\/j.ejca.2017.02.021_bib77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/01.blo.0000069890.31220.b4","article-title":"Radiation therapy for giant cell tumors of bone","volume":"411","author":"Feigenberg","year":"2003","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.021_bib78","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/COC.0b013e3182568fb6","article-title":"Radiotherapy in the management of giant cell tumor of bone","volume":"36","author":"Shi","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.021_bib79","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.4081\/rt.2011.e48","article-title":"Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study","volume":"3","author":"Bhatia","year":"2011","journal-title":"Rare Tumors"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.021_bib80","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00256-015-2117-5","article-title":"Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy","volume":"44","author":"Matcuk","year":"2015","journal-title":"Skelet Radiol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.021_bib81","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12957-016-1034-y","article-title":"Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series","volume":"14","author":"Muller","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.021_bib82","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res"},{"issue":"Suppl. 7","key":"10.1016\/j.ejca.2017.02.021_bib83","first-page":"vii100","article-title":"Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","year":"2012","journal-title":"Ann Oncol"},{"issue":"5 Suppl.","key":"10.1016\/j.ejca.2017.02.021_bib84","doi-asserted-by":"publisher","first-page":"681","DOI":"10.6004\/jnccn.2013.0200","article-title":"Updates in the treatment of bone cancer","volume":"11","author":"Biermann","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2017.02.021_bib85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13569-016-0047-1","article-title":"UK guidelines for the management of bone sarcomas","volume":"6","author":"Gerrand","year":"2016","journal-title":"Clin Sarcoma Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T02:10:11Z","timestamp":1658887811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":85,"alternative-id":["S0959804917307876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Giant cell tumour of bone in the denosumab era","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}